Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

M.V. Dieci; P. Conte; G. Bisagni; A.A. Brandes; A. Frassoldati; L. Cavanna; A. Musolino; F. Giotta; A. Rimanti; O. Garrone; E. Bertone; K. Cagossi; S. Sarti; A. Ferro; F. Piacentini; A. Maiorana; E. Orvieto; M. Sanders; F. Miglietta; S. Balduzzi; R. D'Amico; V. Guarneri

doi:10.1093/annonc/mdz007

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

M.V. Dieci, P. Conte, G. Bisagni, A.A. Brandes, A. Frassoldati, L. Cavanna, A. Musolino, F. Giotta, A. Rimanti, O. Garrone, E. Bertone, K. Cagossi, S. Sarti, A. Ferro, F. Piacentini, A. Maiorana, E. Orvieto, M. Sanders, F. Miglietta, S. BalduzziR. D'Amico, V. Guarneri

Research output: Contribution to journal › Article

Abstract

Background There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm. Patients and methods Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan-Meier curves were estimated for patients with TILs ≥20% and TILs

Original language	English
Pages (from-to)	418-423
Number of pages	6
Journal	Annals of Oncology
Volume	30
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdz007
Publication status	Published - Mar 1 2019

Keywords

anthracycline
eosin
hematoxylin
taxane derivative
trastuzumab
adult
Article
cancer adjuvant therapy
cancer prognosis
cancer staging
clinical evaluation
cohort analysis
disease free survival
early cancer
female
follow up
human
human epidermal growth factor receptor 2 positive breast cancer
major clinical study
middle aged
multicenter study (topic)
phase 3 clinical trial (topic)
postmenopause
priority journal
staining
treatment duration
treatment outcome
tumor associated leukocyte

Access to Document

10.1093/annonc/mdz007

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063729481&doi=10.1093%2fannonc%2fmdz007&partnerID=40&md5=9dd92036302174958dc37e2bc2e2c20a

Fingerprint Dive into the research topics of 'Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer'. Together they form a unique fingerprint.

Cite this

Dieci, M. V., Conte, P., Bisagni, G., Brandes, A. A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Piacentini, F., Maiorana, A., Orvieto, E., Sanders, M., Miglietta, F., ... Guarneri, V. (2019). Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Annals of Oncology, 30(3), 418-423. https://doi.org/10.1093/annonc/mdz007

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. / Dieci, M.V.; Conte, P.; Bisagni, G.; Brandes, A.A.; Frassoldati, A.; Cavanna, L.; Musolino, A.; Giotta, F.; Rimanti, A.; Garrone, O.; Bertone, E.; Cagossi, K.; Sarti, S.; Ferro, A.; Piacentini, F.; Maiorana, A.; Orvieto, E.; Sanders, M.; Miglietta, F.; Balduzzi, S.; D'Amico, R.; Guarneri, V.

In: Annals of Oncology, Vol. 30, No. 3, 01.03.2019, p. 418-423.

Research output: Contribution to journal › Article

Dieci, MV , Conte, P , Bisagni, G, Brandes, AA, Frassoldati, A, Cavanna, L, Musolino, A , Giotta, F, Rimanti, A, Garrone, O, Bertone, E, Cagossi, K, Sarti, S, Ferro, A, Piacentini, F, Maiorana, A, Orvieto, E, Sanders, M, Miglietta, F, Balduzzi, S, D'Amico, R & Guarneri, V 2019, 'Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer', Annals of Oncology, vol. 30, no. 3, pp. 418-423. https://doi.org/10.1093/annonc/mdz007

Dieci, M.V. ; Conte, P. ; Bisagni, G. ; Brandes, A.A. ; Frassoldati, A. ; Cavanna, L. ; Musolino, A. ; Giotta, F. ; Rimanti, A. ; Garrone, O. ; Bertone, E. ; Cagossi, K. ; Sarti, S. ; Ferro, A. ; Piacentini, F. ; Maiorana, A. ; Orvieto, E. ; Sanders, M. ; Miglietta, F. ; Balduzzi, S. ; D'Amico, R. ; Guarneri, V. / Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. In: Annals of Oncology. 2019 ; Vol. 30, No. 3. pp. 418-423.

@article{4b6956b5b85d4126bb7a40ae7a1c315e,

title = "Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer",

abstract = "Background There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm. Patients and methods Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan-Meier curves were estimated for patients with TILs ≥20% and TILs ",

keywords = "anthracycline, eosin, hematoxylin, taxane derivative, trastuzumab, adult, Article, cancer adjuvant therapy, cancer prognosis, cancer staging, clinical evaluation, cohort analysis, disease free survival, early cancer, female, follow up, human, human epidermal growth factor receptor 2 positive breast cancer, major clinical study, middle aged, multicenter study (topic), phase 3 clinical trial (topic), postmenopause, priority journal, staining, treatment duration, treatment outcome, tumor associated leukocyte",

author = "M.V. Dieci and P. Conte and G. Bisagni and A.A. Brandes and A. Frassoldati and L. Cavanna and A. Musolino and F. Giotta and A. Rimanti and O. Garrone and E. Bertone and K. Cagossi and S. Sarti and A. Ferro and F. Piacentini and A. Maiorana and E. Orvieto and M. Sanders and F. Miglietta and S. Balduzzi and R. D'Amico and V. Guarneri",

note = "cited By 8",

year = "2019",

month = mar,

day = "1",

doi = "10.1093/annonc/mdz007",

language = "English",

volume = "30",

pages = "418--423",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "3",

}

TY - JOUR

T1 - Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

AU - Dieci, M.V.

AU - Conte, P.

AU - Bisagni, G.

AU - Brandes, A.A.

AU - Frassoldati, A.

AU - Cavanna, L.

AU - Musolino, A.

AU - Giotta, F.

AU - Rimanti, A.

AU - Garrone, O.

AU - Bertone, E.

AU - Cagossi, K.

AU - Sarti, S.

AU - Ferro, A.

AU - Piacentini, F.

AU - Maiorana, A.

AU - Orvieto, E.

AU - Sanders, M.

AU - Miglietta, F.

AU - Balduzzi, S.

AU - D'Amico, R.

AU - Guarneri, V.

N1 - cited By 8

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm. Patients and methods Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan-Meier curves were estimated for patients with TILs ≥20% and TILs

AB - Background There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm. Patients and methods Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan-Meier curves were estimated for patients with TILs ≥20% and TILs

KW - anthracycline

KW - eosin

KW - hematoxylin

KW - taxane derivative

KW - trastuzumab

KW - adult

KW - Article

KW - cancer adjuvant therapy

KW - cancer prognosis

KW - cancer staging

KW - clinical evaluation

KW - cohort analysis

KW - disease free survival

KW - early cancer

KW - female

KW - follow up

KW - human

KW - human epidermal growth factor receptor 2 positive breast cancer

KW - major clinical study

KW - middle aged

KW - multicenter study (topic)

KW - phase 3 clinical trial (topic)

KW - postmenopause

KW - priority journal

KW - staining

KW - treatment duration

KW - treatment outcome

KW - tumor associated leukocyte

U2 - 10.1093/annonc/mdz007

DO - 10.1093/annonc/mdz007

M3 - Article

VL - 30

SP - 418

EP - 423

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -